Literature DB >> 21951105

Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome.

Marco DiBonaventura1, Shawn X Sun, Susan C Bolge, Jan-Samuel Wagner, Reema Mody.   

Abstract

OBJECTIVES: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Prevalence estimates of IBS vary widely, from 10 to 15%, in the U.S. However, few studies have examined constipation predominant IBS (IBS-C), a subtype of IBS. The aim of this study was to assess the effect of IBS-C on health-related quality of life (HRQOL), work productivity and activity impairment, and health care resource use.
METHODS: Using data from the 2007 U.S. National Health and Wellness Survey, IBS-C patients (n = 789) were compared to a propensity-score matched comparison group (n = 789). Differences between the groups were examined on HRQOL (SF-12v2), work productivity and activity impairment (WPAI questionnaire), and self-reported resource use in the last 6 months.
RESULTS: Patients with IBS-C reported significantly lower levels of HRQOL (physical component summary score: 41.55 [95% CI: 40.72-42.37] versus 44.49 [95% CI: 43.67-45.31]; mental component summary score: 40.58 [95% CI: 39.75-41.40] vs. 45.87 [95% CI: 45.04-46.70]) and significantly higher mean levels of presenteeism (31.72% [95% CI: 28.25%-35.61%] vs. 21.43% [95% CI: 19.03%-24.15%]), overall work impairment (35.54% [95% CI: 31.76%-39.76%] vs. 25.29% [95% CI: 22.59%-28.30%]), and activity impairment (45.78% [95% CI: 43.08%-48.66%] vs. 33.03% [95% CI: 31.08%-35.11%]) than matched comparators (all P values < 0.01). Patients with IBS-C reported significantly more provider visits (8.07 [95% CI: 7.38-8.82] vs. 5.55 [95% CI: 5.07-6.08]) and emergency room visits (0.57 [95% CI: 0.46-0.70] vs. 0.36 [95% CI: 0.29-0.45]) in the past 6 months (all Ps < 0.01). No statistically significant differences between the groups were observed in absenteeism or the number of the days hospitalized.
CONCLUSIONS: IBS-C was associated with poorer HRQOL, greater work productivity loss and activity impairment, and greater healthcare resource use. Limitations include the study's cross-sectional design and its self-reported nature. Nevertheless, improved management of IBS-C may reduce the humanistic and economic burden of the condition and benefit patients, employers, and the healthcare system.

Entities:  

Mesh:

Year:  2011        PMID: 21951105     DOI: 10.1185/03007995.2011.623157

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  24 in total

1.  Obesity and irritable bowel syndrome: a comprehensive review.

Authors:  Octavia Pickett-Blakely
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

2.  Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups.

Authors:  Young Ah Goo; Kevin Cain; Monica Jarrett; Lynne Smith; Joachim Voss; Ernie Tolentino; Joyce Tsuji; Yihsuan S Tsai; Alexandre Panchaud; David R Goodlett; Robert J Shulman; Margaret Heitkemper
Journal:  J Proteome Res       Date:  2012-10-26       Impact factor: 4.466

Review 3.  Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.

Authors:  Paul S J Miller; Harry Hill; Fredrik L Andersson
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

4.  Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.

Authors:  Jessica L Buono; Stavros Tourkodimitris; Phil Sarocco; Jeffrey M Johnston; Robyn T Carson
Journal:  Am Health Drug Benefits       Date:  2014-08

5.  Indirect effect of sleep on abdominal pain through daytime dysfunction in adults with irritable bowel syndrome.

Authors:  Pei-Lin Yang; Robert L Burr; Diana T Buchanan; Kenneth C Pike; Kendra J Kamp; Margaret M Heitkemper
Journal:  J Clin Sleep Med       Date:  2020-10-15       Impact factor: 4.062

Review 6.  Recent developments in the pathophysiology of irritable bowel syndrome.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 7.  Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

Authors:  Khaled A Jadallah; Susan M Kullab; David S Sanders
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 8.  Managing irritable bowel syndrome.

Authors:  Joyce K Anastasi; Bernadette Capili; Michelle Chang
Journal:  Am J Nurs       Date:  2013-07       Impact factor: 2.220

9.  The Treatment of Constipation-Predominant Irritable Bowel Syndrome with Acupuncture and Moxibustion: A Case Report.

Authors:  Joyce K Anastasi; Bernadette Capili
Journal:  J Chin Med       Date:  2012-06

10.  Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom.

Authors:  Marco Dacosta Dibonaventura; Mercedes Prior; Pablo Prieto; Josep Fortea
Journal:  Clin Exp Gastroenterol       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.